BCL2 and serous adenocarcinoma: Munjishvili et al. [31] suggested that several immunohistochemical markers, including bcl-2 and CA-125, are useful for differential diagnosis of borderline ovarian tumours with low-grade serous carcinomas and benign cystadenomas.